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This Month in the Journal
The 6 years I spent working on the Journal have been
an honor and a privilege. I vividly remember walking
into the ofﬁce on my ﬁrst day as an editorial fellow,
seeing a stack of at least 25 manuscripts in my in-box,
and wondering what the heck I had gotten myself into.
But here we are, some 7,000 manuscripts later, and I
can’t believe how the time has ﬂown. I am extraordi-
narily grateful to Steve Warren for the opportunity to
work on the Journal and for his mentorship. Our work
was much easier thanks to the people at the University
of Chicago Press, especially Everett Conner, Peggy Per-
kins, and Alec Dinwoodie. The rest of the AJHG staff
has been phenomenal, and I feel very fortunate to have
worked with them. Without seeing an editorial ofﬁce in
action ﬁrst hand, I don’t think you can truly appreciate
how difﬁcult it is to juggle authors, reviewers, readers,
and the publisher and to keep everybody relatively happy.
Brava to our managing editor, Carissa Gilman, who has
managed to do this with professionalism and grace un-
der pressure. Although I am sorry that our time with
the Journal is coming to an end, I am looking forward
to seeing some of the exciting changes that Cynthia and
her staff are cooking up. I hope they enjoy the work as
much as I have.
KATE GARBER
Inconsistent Haplotype Blocks, by Nothnagel and
Rohde (p. 988)
Haplotype blocks, the HapMap, tagging SNPs: we hear
quite frequently about these concepts and their promise
for use in genetic association studies. With increasing re-
search, it is becoming apparent that haplotype blocks
are not the concrete structural elements that they may
at ﬁrst have seemed; rather, they are impacted by such
factors as SNP density and sample size. To determine
the precision with which haplotype blocks capture ge-
netic variation, Nothnagel and Rohde compared haplo-
type blocks that were deﬁned through two complemen-
tary and interdigitated sets of SNPs. Their approach al-
lowed them to circumvent confounding inﬂuences of
marker density and population selection on haplotype-
block deﬁnition, because the marker sets were of similar
density, came from the same genetic regions, and were
genotyped in the same sample. Even at high marker den-
sities, the particular SNP set chosen had a large effect
on the haplotype-block borders, haplotype frequencies,
and tagSNP selection, so genetic variation is not fully
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captured when one relies on these marker-selectionmeth-
ods. Although these approaches can be useful, trade-offs
still exist between reductions in genotyping effort and
loss of information.
Discriminating Three-Dimensional Facial Morphology,
by Hammond et al. (p. 999)
Clinical geneticists often begin their examination of a
patient with a careful appraisal of craniofacial abnormal-
ities. Disorders such as Noonan syndrome, 22q11 dele-
tion syndrome, Smith-Magenis syndrome, and Williams
syndrome are associated with characteristic facies that
can provide clues to the underlying disease. Here, Ham-
mond et al. expand on their previous work in 3-D face
analysis, using dense surface models to develop a system
that, through comparisons of facial features, can distin-
guish patients of each of the above-named syndromes
from each other and from controls. They began by using
a large number of cases and controls to establish views
of the average face of each group. During this process,
they were also able to determine which speciﬁc regions
of the face are instrumental in the discrimination pro-
cedure. Their system was successful in correctly classi-
fying 89% of 320 randomly selected affected children.
Smith-Magenis syndrome was the most difﬁcult to dis-
tinguish, with 78% of cases correctly identiﬁed, andWil-
liams syndrome was the easiest, with 96% correct.Ham-
mond et al. then used the system to evaluate four adult
males with unconﬁrmed Williams syndrome. According
to the measurements, three of the four were recognized
as patients with Williams syndrome. Indeed, when mo-
lecular testing was performed, the diagnoses based on
facial morphology were conﬁrmed: three patients have
a deletion on 7q11.23, whereas the fourth individual
has a wild-type allele at that locus. The system will not
only be a great instructional tool for clinical geneticists,
but it will also serve as an invaluable resource for ob-
taining additional data for evaluation of genotype-phe-
notype relationships and examination of how the facial
abnormalities of a syndrome change with age.
Identiﬁcation of BBS9, by Nishimura et al. (p. 1021)
Bardet-Biedl Syndrome (BBS) is an autosomal recessive
disorder involving obesity, retinopathy, polydactyly, re-
nal abnormalities, learning disabilities, and hypogeni-
talism. Although eight loci have already been linked to
BBS, mutations in the genes at BBS1-8 account for only
∼50% of the known cases of the disease. Nishimura
et al. have identiﬁed the locus and the gene of BBS9.
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They began with a comparative genomic analysis that
exploited the fact that the genomes of both Trypano-
soma cruzi and Leishmania major but not those of Giar-
dia lamblia or Saccharomyces cerevisiae contain BBS
orthologs. By determining which of the 35,838 human
genes have orthologs in T. cruzi and L. major and ex-
cluding those with partners in G. lamblia and S. cere-
visiae, the authors were left with a set of 366 potential
BBS genes. Of these 366, 19 were also found to be aber-
rantly expressed in the eyes of Bbs4-knockout mice, a
model in which photoreceptors are absent. Support for
the involvement of these 19 genes with BBS is provided
by the fact that 7 of the 8 known BBS genes are within
this group. To further narrow the number of candidates,
Nishimura et al. identiﬁed new potential BBS loci by
homozygosity mapping in small consanguineous BBS-
affected families. Nineteen candidate regions were iden-
tiﬁed, and comparison of these loci with the set of po-
tential genes identiﬁed through genome comparisons sug-
gests that three genes might play a role in BBS: DPCD,
UNCII9, and B1. A B1 splicing mutation was identiﬁed
in one of the BBS-affected families, and six other B1
mutations were then found in a different set of unrelated
probands with BBS. The search continues for new genes
that contribute to this heterogeneous syndrome.
Mannose Receptor in Enzyme Therapy, by Du et al.
(p. 1061)
There are a couple of phenotypes associated with deﬁ-
ciency of lysosomal acid lipase (LAL), the enzyme crucial
for hydrolysis of triglycerides and cholesteryl esters in
lysosomes. These are cholesteryl ester storage disease
(CESD) and themore severeWolmandisease (WD),which
is fatal within a few months of birth because of the
accumulation in several organs of macrophages con-
taining cholesteryl esters and triglycerides. Enzyme re-
placement therapy shows promise for the treatment of
these disorders. In an LAL-null mouse model, treatment
with human LAL produced in Pichia pastoris results in
signiﬁcant improvement of hepatosplenomegaly and lip-
id accumulation. Improvement in the liver of these an-
imals is due primarily to reductions in lipid storage in
Kuppfer cells, whereas there is no improvement noted
in hepatocytes. In an attempt to better understand the
uptake and delivery of the LAL replacement therapy in
this model, Du et al. compared the use of P. pastoris–
produced human LAL (phLAL), which is highly man-
nosylated, to CHO cell–produced human LAL (chLAL),
which includes more-complex structures. In contrast to
phLAL, chLAL is able to clear the accumulated lipids
from hepatocytes. Previous work had indicated that in-
corporation of phLAL into the lysosomes of J774 cells
was dependent on the macrophage mannose receptor
(MMR). Du et al. show that this process can be al-
tered when phLAL is used to treat lal/;MMR/ dou-
ble-knockout mice. In this case, phLAL is cleared much
more slowly from plasma and is able to mediate clear-
ance of lipids from hepatocytes. The work of Du et al.
highlights the importance of the uptake mechanisms for
the efﬁcacy of enzyme replacement therapy. It also has
greater implications than the treatment for WD and
CESD, because LAL has also been shown to have use
in treating atherosclerosis in a mouse model.
X-Chromosomal Haplotype in LHON, by Hudson et
al. (p. 1086)
Since association studies for the analysis of complex dis-
orders have become common practice, it is clear that, in
many diseases, a number of factors interact to affect the
penetrance of a phenotype. In Leber hereditary optic neu-
ropathy (LHON), a disease consisting of bilateral visual
failure, 95% of cases are due to one of three mitochon-
drial mutations: 3460GrA in MTND1, 11778GrA in
MTND4, or 14454TrC in MTND6. Yet only ∼50% of
males and ∼10% of females carrying a mutation develop
symptoms. What other factors are involved with LHON?
Previous work has suggested that a modiﬁer locus resides
on the X chromosome, but studies have been unsuc-
cessful in identifying the region involved. Here, by re-
stricting their cases to those with the mitochondrial
mutations at 170% heteroplasmy and by starting their
search with nonparametric linkage analysis in an iso-
lated cohort of Finnish families, Hudson et al. mapped
a region on the X chromosome that is strongly associated
with LHON. After the association with this region was
conﬁrmed in other European populations, a sample of
150 European men with LHON were used to deﬁne a
high-risk haplotype that is more highly represented in
males with LHON than in controls. Similarly, females
who are homozygous for the X-chromosomal haplotype
also demonstrate a higher risk of developing LHON.
The identiﬁcation of this nuclear modiﬁer of LHON-
associated mitochondrial mutations should help us to
better understand the expression of this phenotype, and,
in the future, it also may assist in genetic counseling of
families with LHON through better predictions of dis-
ease outcome.
KATHRYN GARBER AND ROBIN E. WILLIAMSON
Deputy Editors
